Ukraine reconstruction:
one stock to benefit

(Full access for Members only)

Ukraine reconstruction: one stock to benefit

1 November 2024

The stock featured in this report is one of the most asymmetric opportunities that I have come across in my career.

It's a Ukrainian business, and heavily affected by the war.

The stock is down nearly 90%.

The company, however, is profitable and debt-free – even today.

Its governance is much better than you'd expect, because of a unique twist.

If or when hostilities end and Ukraine achieves a degree of normalisation, the stock will likely become the focus of investor money pushing into the country.

The reconstruction of Ukraine will be a triple-digit billion market opportunity – but opportunities for private investors to get in are scarce.

The stock discussed in this report, however, is easy to trade. It's listed on a major Western stock exchange that anyone with a brokerage account can access.

A normalisation of operations would probably yield 3-4x, and longer term the stock could even achieve 10x.

Not a Member yet? Sign up for a Membership - just USD 49/year.
Already a Member? Log into your account to download the report.

Most recent

Latest reports (for Members only)

2-2.5x from an investment holding liquidation

2-2.5x from an investment holding liquidation

This AIM-listed small-cap will likely return all its capital to shareholders. Underresearched by investors, it's an opportunity that shouldn't even exist – but it does.

Ukraine reconstruction: one stock to benefit

Ukraine reconstruction: one stock to benefit

If or when the war in Ukraine ends, this stock will likely become the focus of investor money pushing into the country.

Actinium-225, aka "the world's rarest drug"

Actinium-225, aka "the world's rarest drug"

This little-known Western European company could become the global market leader for supplying the uber-rare "Ac-225", a potent weapon to treat cancer.